- Home
- TDOC vs EYPT Comparison
TDOC vs EYPT Comparison
Compare TDOC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDOC | EYPT |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2015 | 2005 |
Fundamental Metrics
Financial Performance| Metric | TDOC | EYPT |
|---|---|---|
| Price | $7.62 | $16.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | $9.54 | ★ $28.75 |
| AVG Volume (30 Days) | ★ 4.3M | 1.2M |
| Earning Date | 02-25-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,528,199,000.00 | $42,339,000.00 |
| Revenue This Year | $0.13 | N/A |
| Revenue Next Year | $1.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.35 | $3.91 |
| 52 Week High | $15.21 | $19.11 |
Technical Indicators
Market Signals| Indicator | TDOC | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 49.11 |
| Support Level | $6.90 | $16.67 |
| Resistance Level | $8.06 | $18.20 |
| Average True Range (ATR) | 0.27 | 0.98 |
| MACD | 0.07 | -0.29 |
| Stochastic Oscillator | 53.59 | 4.49 |
Price Performance
Historical ComparisonAbout TDOC Teladoc Health Inc.
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with improved convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.